Get the Stockscreener App
18.48
3.24%
0.58
Theravance Biopharma Inc stock is traded at $18.48, with a volume of 566.46K.
It is up +3.24% in the last 24 hours and up +31.91% over the past month.
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
See More
Previous Close:
$17.90
Open:
$17.77
24h Volume:
566.46K
Relative Volume:
1.31
Market Cap:
$936.43M
Revenue:
$62.02M
Net Income/Loss:
$-45.65M
P/E Ratio:
-20.09
EPS:
-0.92
Net Cash Flow:
$-9.60M
1W Performance:
+6.27%
1M Performance:
+31.91%
6M Performance:
+96.39%
1Y Performance:
+92.30%
1-Day Range:
$17.50
$18.57
1-Week Range:
$17.25
$18.58
52-Week Range:
$7.90
$18.96
Theravance Biopharma Inc Stock (TBPH) Company Profile
Name
Theravance Biopharma Inc
Sector
Industry
Phone
650-808-6000
Address
UGLAND HOUSE, SOUTH CHURCH STREET, GEORGE TOWN, GRAND CAYMAN
Compare TBPH with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TBPH
Theravance Biopharma Inc
|
18.48 | 907.04M | 62.02M | -45.65M | -9.60M | -0.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Theravance Biopharma Inc Stock (TBPH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-12-25 | Initiated | B. Riley Securities | Buy |
| Aug-06-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Apr-12-24 | Initiated | BTIG Research | Buy |
| Jan-08-24 | Downgrade | Evercore ISI | Outperform → In-line |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Nov-05-21 | Upgrade | JP Morgan | Underweight → Neutral |
| Sep-15-21 | Downgrade | JP Morgan | Overweight → Underweight |
| Aug-25-21 | Downgrade | Morgan Stanley | Overweight → Underweight |
| Aug-24-21 | Downgrade | Cowen | Outperform → Market Perform |
| Oct-14-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jul-07-20 | Initiated | JP Morgan | Overweight |
| Jun-15-20 | Initiated | Morgan Stanley | Equal-Weight |
| May-13-20 | Initiated | Cowen | Outperform |
| Jan-08-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-06-19 | Upgrade | Robert W. Baird | Underperform → Neutral |
| Oct-29-19 | Initiated | H.C. Wainwright | Buy |
| Mar-29-18 | Resumed | Piper Jaffray | Overweight |
| Aug-17-17 | Initiated | Evercore ISI | Outperform |
| Jun-16-17 | Initiated | Cantor Fitzgerald | Overweight |
| May-11-17 | Reiterated | Needham | Buy |
| Dec-21-16 | Initiated | Needham | Buy |
| Nov-03-16 | Initiated | Piper Jaffray | Overweight |
| Oct-12-16 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Aug-03-16 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Jun-20-16 | Initiated | Guggenheim | Buy |
| Jun-20-16 | Reiterated | Leerink Partners | Outperform |
| May-12-16 | Initiated | Leerink Partners | Outperform |
| May-05-16 | Downgrade | BofA/Merrill | Buy → Neutral |
| Feb-03-15 | Upgrade | Robert W. Baird | Underperform → Neutral |
View All
Theravance Biopharma Inc Stock (TBPH) Latest News
Theravance's Q3 Earnings Surpass Estimates, Revenues Match - MSN
[Form 4] Theravance Biopharma, Inc. Insider Trading Activity - Stock Titan
CEO Winningham Surrenders 56,817 Of Theravance Biopharma Inc [TBPH] - TradingView
Can Theravance Biopharma Inc. stock beat analyst upgrades - newser.com
Why pension funds invest in Theravance Biopharma Inc. (0TB) stock2025 Growth vs Value & AI Based Buy/Sell Signal Reports - newser.com
Is Theravance Biopharma Inc. stock attractive for passive investors2025 Technical Patterns & Risk Controlled Swing Alerts - newser.com
Theravance Biopharma (TBPH) is a Top-Ranked Growth Stock: Should You Buy? - MSN
Why Theravance Biopharma Inc. stock is rated strong buy2025 Fundamental Recap & Accurate Trade Setup Notifications - newser.com
Theravance Biopharma to host virtual KOL event on ampreloxetine study - Investing.com
Theravance Biopharma to host virtual KOL event on ampreloxetine study By Investing.com - Investing.com India
Theravance (NASDAQ: TBPH) Sets Ampreloxetine Call on Phase 3 Data Expected in Q1 - Stock Titan
Is Theravance Biopharma Inc. (0TB) stock a fit for income portfoliosJuly 2025 Review & Technical Analysis for Trade Confirmation - newser.com
How Theravance Biopharma Inc. (0TB) stock reacts to fiscal policiesWeekly Profit Report & Long-Term Safe Return Strategies - newser.com
Theravance Biopharma Inc. stock trendline breakdownQuarterly Profit Report & Accurate Technical Buy Alerts - newser.com
Is Theravance Biopharma Inc. stock cheap at current valuation2025 Volume Leaders & Weekly Return Optimization Alerts - newser.com
Will a bounce in Theravance Biopharma Inc. offer an exit2025 Biggest Moves & Free High Accuracy Swing Entry Alerts - newser.com
Can Theravance Biopharma Inc. stock deliver consistent earnings growthQuarterly Performance Summary & Reliable Price Breakout Signals - newser.com
Theravance Biopharma Inc. stock retracement – recovery analysisTrade Risk Assessment & Low Volatility Stock Suggestions - newser.com
Theravance Biopharma (NASDAQ: TBPH) to Join Evercore, Oppenheimer Investor Conferences - Stock Titan
News impact scoring models applied to Theravance Biopharma Inc.Earnings Overview Summary & AI Driven Price Predictions - newser.com
What momentum shifts mean for Theravance Biopharma Inc.2025 Earnings Impact & Technical Entry and Exit Tips - newser.com
Comparing Theravance Biopharma Inc. in custom built stock radarsTake Profit & Weekly High Conviction Trade Ideas - newser.com
Can Theravance Biopharma Inc. (0TB) stock hit consensus price targetsJuly 2025 Breakouts & Expert-Curated Trade Recommendations - newser.com
What indicators show strength in Theravance Biopharma Inc.2025 EndofYear Setup & Expert Verified Movement Alerts - newser.com
BTIG Hosts Virtual Meeting Featuring (TBPH) on November 24 - GuruFocus
Why Theravance Biopharma Inc. (0TB) stock benefits from AI revolutionJuly 2025 Update & High Yield Stock Recommendations - newser.com
Theravance Biopharma Inc Stock (TBPH) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.38%
1.42%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):